Four weeks after anti-CD38 CAR-T cell infusion, 4/6 patients (66.7%) achieved CR or CRi, with a median time to CR or CRi of 191 days, a median OS of 7.9 months, and a median leukemia-free survival (LFS) of 6.4 months. The gene discussed is CD38; the disease is leukemia.